Urinary concentrations of colistimethate and formed colistin after intravenous administration in patients with multidrug-resistant gram-negative bacterial infections

Sonia Luque, Carol Escaño, Luisa Sorli, Jian Li, Nuria Campillo, Juan Pablo Horcajada, Esther Salas, Santiago Grau

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)

Abstract

© 2017 American Society for Microbiology. All Rights Reserved. Limited information is available on the urinary excretion of colistin in infected patients. This study aimed to investigate the pharmacokinetics of colistimethate sodium (CMS) and formed colistin in urine in patients with multidrug-resistant (MDR) Gram-negative bacterial infections. A pharmacokinetic study was conducted on 12 patients diagnosed with an infection caused by an extremely drug-resistant (XDR) P. aeruginosa strain and treated with intravenous CMS. Fresh urine samples were collected at 2-h intervals, and blood samples were collected predose (Cmin ss) and at the end of the CMS infusion (Cmax ss) for measurement of concentrations of CMS and formed colistin using high-performance liquid chromatography (HPLC). CMS urinary recovery was determined as the summed amount of CMS and formed colistin recovered in urine for each 2-h interval divided by the CMS dose. There were 12 enrolled patients, 9 of whom were male (75%). Data [median (range)] were as follows: age, 65.5 (37 to 86) years; colistimethate urinary recovery 0 to 6 h, 42.6% (2.9% to 72.8%); range of concentrations of colistin in urine, <0.1 to 95.4 mg/liter; Cmin ss and Cmax ss of colistin in plasma, 0.9 (<0.2 to 1.4) and 0.9 (<0.2 to 1.4) mg/liter, respectively. In 6/12 (50%) patients, more than 40% of the CMS dose was recovered in the urine within the first 6 h after CMS administration. This study demonstrated rapid urinary excretion of CMS in patients within the first 6 h after intravenous administration. In all but one patient, the concentrations of formed colistin in urine were above the MIC for the most predominant isolate of P. aeruginosa in our hospital. Future studies are warranted for optimizing CMS dosage regimens in urinary tract infection (UTI) patients.
Original languageEnglish
Article numbere02595
JournalAntimicrobial Agents and Chemotherapy
Volume61
Issue number8
DOIs
Publication statusPublished - 1 Aug 2017

Keywords

  • Colistin
  • Gram-negative bacteria
  • Pharmacokinetics
  • Urinary tract infections

Fingerprint

Dive into the research topics of 'Urinary concentrations of colistimethate and formed colistin after intravenous administration in patients with multidrug-resistant gram-negative bacterial infections'. Together they form a unique fingerprint.

Cite this